Clinical Benefits of Novartis Entresto Tablets in the PIONEER-HF Trial

Source: Drug Information Network

Heart failure (heart failure) is a serious progressive heart disease in which the heart is unable to fully fill and expel blood, causing the patient to develop weak symptoms.

Recently, Novartis announced that its Entresto tablet has achieved remarkable and superior clinical benefits in the landmark PIONEER-HF trial compared to enalapril, a commonly used drug for heart failure.

Entresto was initially administered in hospital for the treatment of patients with heart failure with reduced ejection fraction (HFrEF) who were admitted to hospital for acute decompensated heart failure (ADHF) events. Related studies The PIONEER-HF trial was designed to assess the efficacy and tolerability of Entresto in the initial hospitalization compared with enalapril (an ACEi) in the treatment of stable HFrEF patients admitted to hospital for ADHF. Sex, and security. 881 patients with an average age of 61 years were enrolled in the trial. Their ejection fraction (EF) was ≤40%, and the amino-terminal pro-type natriuretic peptide (NT-proBNP) ≥1600 pg/mL or b-type natriuretic peptide (BNP) ≥ 400 pg/mL. NT-proBNP is an established biomarker for assessing the severity and prognosis of heart failure.

The primary endpoint of the trial was the change in NT-proBNP levels compared to baseline at the fourth and eighth weeks of treatment.

The results of the trial showed that Entresto reached the primary end point of the trial. The NT-proBNP level was reduced by 47% in the Entresto group and by 25% in the enalapril group, indicating that the Entresto group achieved a statistically significant 29% compared with enalapril. Reduced (95% CI: 0.63, 0.81; P < 0.0001). The Entresto group was observed in the trial, and the level of NT-proBNP was significantly reduced as early as one week after treatment.